全文获取类型
收费全文 | 13607篇 |
免费 | 1399篇 |
国内免费 | 496篇 |
专业分类
耳鼻咽喉 | 58篇 |
儿科学 | 77篇 |
妇产科学 | 54篇 |
基础医学 | 819篇 |
口腔科学 | 942篇 |
临床医学 | 1105篇 |
内科学 | 706篇 |
皮肤病学 | 42篇 |
神经病学 | 414篇 |
特种医学 | 447篇 |
外科学 | 800篇 |
综合类 | 2060篇 |
一般理论 | 3篇 |
预防医学 | 2143篇 |
眼科学 | 103篇 |
药学 | 3689篇 |
19篇 | |
中国医学 | 1836篇 |
肿瘤学 | 185篇 |
出版年
2024年 | 7篇 |
2023年 | 285篇 |
2022年 | 352篇 |
2021年 | 597篇 |
2020年 | 570篇 |
2019年 | 532篇 |
2018年 | 545篇 |
2017年 | 546篇 |
2016年 | 557篇 |
2015年 | 569篇 |
2014年 | 944篇 |
2013年 | 1453篇 |
2012年 | 964篇 |
2011年 | 1020篇 |
2010年 | 722篇 |
2009年 | 719篇 |
2008年 | 795篇 |
2007年 | 710篇 |
2006年 | 609篇 |
2005年 | 533篇 |
2004年 | 368篇 |
2003年 | 308篇 |
2002年 | 280篇 |
2001年 | 253篇 |
2000年 | 205篇 |
1999年 | 146篇 |
1998年 | 108篇 |
1997年 | 112篇 |
1996年 | 79篇 |
1995年 | 66篇 |
1994年 | 73篇 |
1993年 | 75篇 |
1992年 | 63篇 |
1991年 | 42篇 |
1990年 | 37篇 |
1989年 | 35篇 |
1988年 | 39篇 |
1987年 | 32篇 |
1986年 | 25篇 |
1985年 | 23篇 |
1984年 | 19篇 |
1983年 | 12篇 |
1982年 | 12篇 |
1981年 | 13篇 |
1980年 | 15篇 |
1979年 | 5篇 |
1978年 | 5篇 |
1977年 | 7篇 |
1976年 | 5篇 |
1974年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
《Journal of the American Medical Directors Association》2022,23(3):379-386.e3
ObjectivesPreclinical and clinical studies indicate a role for MLC901 (NeuroAiD II) in Alzheimer's disease (AD). The primary aim was to investigate its safety as add-on therapy to standard treatment and the secondary aims its effect on cognition and slowing disease progression.DesignRandomized double-blind placebo-controlled delayed-start study.Setting and ParticipantPatients with mild to moderate probable AD by NINCDS-ADRDA criteria, stable on acetylcholinesterase inhibitors or memantine (n = 125), were randomized to receive MLC901 (early starters) or placebo (delayed starters) for 6 months, followed by a further 6 months when all patients received MLC901, in a delayed-start design (clinical trial registration: ClinicalTrials.gov, NCT03038035).MethodsThe primary outcome measure was occurrence of serious adverse events (SAEs) at 6 months. Secondary outcomes included the Alzheimer's Disease Assessment Scale–Cognitive subscale (ADAS-Cog) and other assessment scales.ResultsThere was no significant difference in the risk of SAEs between early and delayed starters at month (M) 6 (22.6% vs 27.0%, risk difference ?4.4%, 90% CI –16.9% to 8.3%). Similarly, there was no significant difference in the risk of adverse events and the occurrence of stroke or vascular events between early and delayed starters throughout the 12-month study period. Early starters did not differ significantly on ADAS-Cog from delayed starters at M6 [mean difference (MD) ?1.0, 95% CI –3.3 to 1.3] and M12 (MD –2.35, 95% CI –5.45 to 0.74) on intention-to-treat analysis. Other cognitive assessment scales did not show significant differences.Conclusions and ImplicationsThis study of 125 persons with dementia found no evidence of a significant increase in adverse events between MLC901 and placebo, thus providing support for further studies on both efficacy and safety. Analyses suggest the potential of MLC901 in slowing down AD progression, but this requires further confirmation in larger and longer studies using biomarkers for AD. 相似文献
5.
Edwin van der Pol Joshua A. Welsh Rienk Nieuwland 《Journal of thrombosis and haemostasis》2022,20(1):245-251
The Extracellular Vesicle Flow Cytometry Working Group ( http://www.evflowcytometry.org ) is formed by members of the International Society for Extracellular Vesicles (ISEV), the International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH). This working group of flow cytometry experts develops guidelines for best practices regarding flow cytometry detection of extracellular vesicles. To improve rigor and standardization, this working group published a framework outlining the minimal information to report about a flow cytometry experiment on extracellular vesicles (MIFlowCyt-EV) in the Journal of Extracellular Vesicles, the ISEV journal, in 2020. In parallel, an article explaining MIFlowCyt-EV was published in Cytometry Part A, one of the ISAC journals, and now will be introduced to the ISTH as an SSC Communication in the Journal of Thrombosis and Haemostasis. The goal of this SSC Communication is to explain why flow cytometry is becoming the instrument of choice to characterize single extracellular vesicles, the obstacles that have been identified and (mostly) overcome by developing procedures to calibrate flow cytometers, and the relevance of reporting minimal information to improve reliability and reproducibility of experiments in which flow cytometers are used for characterization of extracellular vesicles. 相似文献
6.
文章以温病的治法祛湿法为例,提出讨论式教学法的教学设计,包括建立"三人为师"规则、"发言签"规则,营造讨论气氛,角色分配包括向导、刺头、记录员、法官、汇报人,然后按照"领结模型"展开讨论,最后按照表达意愿、思维技能、学生间互动、内容知识掌握情况等进行评估,旨在培养学生温病学临床思维能力与团队协作能力。 相似文献
7.
《Drug discovery today》2022,27(5):1367-1380
The tremendous advances in genomics, recombinant DNA technology, bioengineering and nanotechnology, in conjunction with the development of high-end computations, have been instrumental in the process of rational design of peptide-based vaccines. The use of peptide vaccines was limited owing to their inherent instability when systemically administered; however, advanced formulation techniques have been developed for their systemic delivery, thereby overcoming their degradation, clearance, cellular uptake and off-target effects. With the rise of sophisticated immunological predictors and experimental techniques, several methodological advances have occurred in this field. This review examines contemporary methods to identify and optimize epitopes, engineer their immunogenic properties and develop their safe and efficient delivery into the host. 相似文献
8.
9.
10.
Alexander D. Sherry MD Kelsey L. Corrigan MD MPH Ramez Kouzy MD Joseph Abi Jaoude MD Yumeng Yang MS Roshal R. Patel MD Douglas J. Totten MD MBA Neil B. Newman MD MS Prajnan Das MD MS MPH Cullen Taniguchi MD PhD Bruce Minsky MD Rebecca A. Snyder MD MPH C. David Fuller MD PhD Ethan Ludmir MD 《Cancer》2023,129(21):3430-3438